Search research articles
Contact Us
Filters
Showing results (181-190 of 198) with videos related to
Page
of 20
Sort By:
The New England Journal of Medicine
|
October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Journal of Clinical Medicine
|
February 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study
Antonello Veccia, Ettore D'Argento, Floriana Morgillo, et al.
Therapeutic Advances in Medical Oncology
|
October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study
Rossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Translational Cancer Research
|
February 4, 2022
Listening understanding and acting (lung): focus on communicational issue in thoracic oncology
Claudia Yvonne Finocchiaro, Alessandra Rota, Vito Barbieri, et al.
Thoracic Cancer
|
December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy
Giuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]"
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Lancet (London, England)
|
November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Quincy Chu, Francesco Perrone, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Cancer Treatment and Research Communications
|
February 26, 2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study
Paolo Bironzo, Alessandro Morabito, Sonia Silipigni, et al.
Journal for Immunotherapy of Cancer
|
October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 198) with videos related to
Sort By:
Page
of 20
The New England Journal of Medicine
|
October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
Journal of Clinical Medicine
|
February 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study
Antonello Veccia, Ettore D'Argento, Floriana Morgillo, et al.
Therapeutic Advances in Medical Oncology
|
October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study
Rossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Translational Cancer Research
|
February 4, 2022
Listening understanding and acting (lung): focus on communicational issue in thoracic oncology
Claudia Yvonne Finocchiaro, Alessandra Rota, Vito Barbieri, et al.
Thoracic Cancer
|
December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy
Giuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]"
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Lancet (London, England)
|
November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Quincy Chu, Francesco Perrone, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Cancer Treatment and Research Communications
|
February 26, 2026
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study
Paolo Bironzo, Alessandro Morabito, Sonia Silipigni, et al.
Journal for Immunotherapy of Cancer
|
October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
Page
of 20